| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -74.34 M USD | -143.45 M USD | -43.29 M USD | -89.37 M USD | -44.06 M USD | -15.42 M USD | -35.21 M USD | -25.20 M USD | -24.10 M USD | -39.10 M USD | -34.70 M USD | -22.62 M USD |
| Depreciation & Amortization | 9.26 M USD | 12.52 M USD | 12.67 M USD | 6.22 M USD | 3.22 M USD | 4.01 M USD | 4.61 M USD | 5.37 M USD | 7.41 M USD | 6.74 M USD | 4.92 M USD | 4.06 M USD |
| Stock-Based Compensation | 29.61 M USD | 31.73 M USD | 13.12 M USD | 14.88 M USD | 16.10 M USD | 14.45 M USD | 11.39 M USD | 11.02 M USD | 9.09 M USD | 13.86 M USD | 16.83 M USD | 20.94 M USD |
| Capital Expenditures | 8.30 M USD | 8.36 M USD | 2.83 M USD | 3.83 M USD | 13.26 M USD | 12.72 M USD | 2.53 M USD | 372000 USD | 1.57 M USD | 5.07 M USD | 3.98 M USD | 7.40 M USD |
| Cash Flow from Investing | 27.41 M USD | 363.17 M USD | 20.24 M USD | -88.13 M USD | -11.95 M USD | 39.98 M USD | -39.30 M USD | 4.72 M USD | 17.66 M USD | 45.10 M USD | 25.74 M USD | -178.38 M USD |
| Cash Flow from Financing | 570000 USD | -102.62 M USD | -6.81 M USD | 230.76 M USD | 15.96 M USD | 20.86 M USD | 2.79 M USD | 57.66 M USD | 29.00 M USD | 76000 USD | 5.30 M USD | 200.33 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | 0 USD | 40.49 M USD | 5.41 M USD | 563000 USD | 0 USD | — | — | — | — | — | — | — |
| Free Cash Flow | -82.65 M USD | -151.81 M USD | -46.12 M USD | -93.19 M USD | -57.33 M USD | -28.13 M USD | -37.74 M USD | -25.57 M USD | -25.66 M USD | -44.16 M USD | -38.68 M USD | -30.03 M USD |
Standard Biotools Inc. is a leading developer and provider of innovative life sciences tools and solutions. This company focuses on empowering researchers by delivering precision instruments and systems essential for high-throughput DNA sequencing, protein analysis, and molecular diagnostics. With a commitment to advancing healthcare and scientific discovery, Standard Biotools provides critical support to industries such as biotechnology, pharmaceuticals, and academic research institutions. Their cutting-edge platforms facilitate more effective and efficient data analysis, enabling breakthroughs in personalized medicine and disease understanding. Headquartered in the United States, Standard Biotools Inc. plays a vital role in the life sciences sector, frequently collaborating with research entities to propel forward the capabilities of modern biological technology. This company's contributions are crucial in addressing global health challenges and paving the way for future innovations in the scientific community.